Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy
Raffaele Coppini(University of Florence), Mark V. Sherrid(NYU Langone Health), Alfonso Bueno‐Orovio(British Heart Foundation), Laura Flink(San Francisco VA Medical Center), Iacopo Olivotto(Azienda Ospedaliero-Universitaria Careggi), Corrado Poggesi(University of Florence), Francesco S. Pavone(National Research Council), Josè Manuel Pioner(University of Florence), Cecilia Ferrantini(University of Florence), Lorenzo Santini(University of Florence), Zhinuo Jenny Wang(University of Auckland), Leonardo Sacconi(University Medical Center Freiburg), Elisabetta Cerbai(University of Florence), Katherine Riedy(NYU Langone Health), Pierluigi Stefàno(Azienda Ospedaliero-Universitaria Careggi), Chiara Palandri(University of Florence), Alessandro Mugelli(University of Florence), Giulia Vitale(University of Florence), Marina Scardigli
Cited by 82
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
|Circulation|2014|1k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837